聯環藥業(600513.SH)擬吸收合併揚州製藥 接手募投項目
格隆匯12月27日丨聯環藥業(600513.SH)公佈,為進一步優化公司管理架構,降低管理成本,提高運營效率,公司擬吸收合併全資子公司揚州製藥有限公司(以下簡稱“揚州製藥”)。吸收合併完成後,公司存續經營,揚州製藥的獨立法人資格將依法啟動註銷程序,其所有資產、股權、債權債務、人員、業務及其他權利與義務將由公司依法承繼。
公司於2015年完成的非公開發行股票募投項目之一的“年產20000kg地塞米松磷酸鈉原料藥建設項目”實施主體將由揚州製藥有限公司變更為公司,該項目的資金金額、用途、實施地點等其他計劃不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.